Sec. 2263. Alteration or waiver of informed consent for clinical investigations
188 words·~1 min read·
/bill/114/hr/6/eh/section-2263A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 520(g)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360j(g)(3) ) is amended— in subparagraph (D), by striking except where subject to such conditions as the Secretary may prescribe, the investigator and inserting the following: except where, subject to such conditions as the Secretary may prescribe— the proposed clinical testing poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of the human subject; or the investigator ; and in the matter following subparagraph (D), by striking subparagraph
(D)and inserting subparagraph (D)(ii) . Section 505(i)(4) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(i)(4) ) is amended by striking except where it is not feasible or it is contrary to the best interests of such human beings and inserting except where it is not feasible, it is contrary to the best interests of such human beings, or the proposed clinical testing poses no more than minimal risk to such human beings and includes appropriate safeguards as prescribed to protect the rights, safety, and welfare of such human beings .
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Sec. 2263
Alteration or waiver of informed consent for clinical investigations
Cites 2Cited by 0 across 0 sources